Synonym
Loureirin B; LR-B; L B; LRB
IUPAC/Chemical Name
1-(4-hydroxyphenyl)-3-(2,4,6-trimethoxyphenyl)propan-1-one
InChi Key
ZPFRAPVRYLGYEC-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H20O5/c1-21-14-10-17(22-2)15(18(11-14)23-3)8-9-16(20)12-4-6-13(19)7-5-12/h4-7,10-11,19H,8-9H2,1-3H3
SMILES Code
O=C(C1=CC=C(O)C=C1)CCC2=C(OC)C=C(OC)C=C2OC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Biological target:
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.
In vitro activity:
LB (loureirin B) down regulated p-ERK and p-JNK in TGF-β1-stimulated fibroblasts, while levels of phosphorylated p38 did not change. LB down regulated protein levels of p-ERK and p-JNK in cultured hypertrophic scar tissue ex vivo.
Reference: Cell Physiol Biochem. 2015;37(2):666-76. https://pubmed.ncbi.nlm.nih.gov/26344923/
In vivo activity:
In vivo studies showed that loureirin B significantly prolonged the tail bleeding time and reduced the weight and size of arterial thrombus, reduced hydroxyproline level, and partly cured liver fibrosis in mice.
Reference: Evid Based Complement Alternat Med. 2017;2017:9425963. https://pubmed.ncbi.nlm.nih.gov/29234445/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMF |
30.0 |
94.83 |
|
| DMSO |
93.3 |
295.03 |
|
| DMSO:PBS (pH 7.2) (1:2) |
0.3 |
1.04 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
316.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Zhang J, Mo L, Huang H, Xu J, Fan Y, Li W, Wang H, Zhou C, Fang H, He W, Chen Z, Liu Y. Loureirin B downregulates osteoclast differentiation of bone marrow macrophages by targeting the MAPK signaling pathway. Sci Rep. 2022 Aug 23;12(1):14382. doi: 10.1038/s41598-022-18287-5. PMID: 35999378; PMCID: PMC9399088.
2. He T, Bai X, Yang L, Fan L, Li Y, Su L, Gao J, Han S, Hu D. Loureirin B Inhibits Hypertrophic Scar Formation via Inhibition of the TGF-β1-ERK/JNK Pathway. Cell Physiol Biochem. 2015;37(2):666-76. doi: 10.1159/000430385. PMID: 26344923.
3. Jiang Y, Zhang G, Yan D, Yang H, Ye Z, Ma T. Bioactivity-Guided Fractionation of the Traditional Chinese Medicine Resina Draconis Reveals Loureirin B as a PAI-1 Inhibitor. Evid Based Complement Alternat Med. 2017;2017:9425963. doi: 10.1155/2017/9425963. Epub 2017 Sep 18. PMID: 29234445; PMCID: PMC5634571.
4. Bai X, He T, Liu J, Wang Y, Fan L, Tao K, Shi J, Tang C, Su L, Hu D. Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β/Smad pathway. Exp Dermatol. 2015 May;24(5):355-60. doi: 10.1111/exd.12665. Epub 2015 Mar 9. PMID: 25683490.
In vitro protocol:
1. Zhang J, Mo L, Huang H, Xu J, Fan Y, Li W, Wang H, Zhou C, Fang H, He W, Chen Z, Liu Y. Loureirin B downregulates osteoclast differentiation of bone marrow macrophages by targeting the MAPK signaling pathway. Sci Rep. 2022 Aug 23;12(1):14382. doi: 10.1038/s41598-022-18287-5. PMID: 35999378; PMCID: PMC9399088.
2. He T, Bai X, Yang L, Fan L, Li Y, Su L, Gao J, Han S, Hu D. Loureirin B Inhibits Hypertrophic Scar Formation via Inhibition of the TGF-β1-ERK/JNK Pathway. Cell Physiol Biochem. 2015;37(2):666-76. doi: 10.1159/000430385. PMID: 26344923.
In vivo protocol:
1. Jiang Y, Zhang G, Yan D, Yang H, Ye Z, Ma T. Bioactivity-Guided Fractionation of the Traditional Chinese Medicine Resina Draconis Reveals Loureirin B as a PAI-1 Inhibitor. Evid Based Complement Alternat Med. 2017;2017:9425963. doi: 10.1155/2017/9425963. Epub 2017 Sep 18. PMID: 29234445; PMCID: PMC5634571.
2. Bai X, He T, Liu J, Wang Y, Fan L, Tao K, Shi J, Tang C, Su L, Hu D. Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β/Smad pathway. Exp Dermatol. 2015 May;24(5):355-60. doi: 10.1111/exd.12665. Epub 2015 Mar 9. PMID: 25683490.
1. Yin, S., Hu, Q., Luo, J., et al. Loureirin B, an essential component of Sanguis Draxonis, inhibits Kv1.3 channel and suppresses cytokine release from Jurkat T cells. Cell Biosci. 4, 78 (2014).
2. He, T., Bai, X., Yang, L., et al. Loureirin B inhibits hypertrophic scar formation via inhibition of the TGF-β1-ERK/JNK pathway. Cell Physiol. Biochem. 37(2), 666-676 (2015).
3. Sha, Y., Zhang, Y., Cao, J., et al. Loureirin B promotes insulin secretion through inhibition of KATP channel and influx of intracellular calcium. J. Cell. Biochem. 119(2), 2012-2021 (2017).
